Evogene Ltd.

Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, Spain REHOVOT, Israel, Oct. 26, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in two upcoming industry conferences in Europe: BIO-Europe, to be held November 9-11, 2026, in Cologne, Germany, and Drug Discovery Chemistry Europe, to be held November 10-12, 2026, in Barcelona, Spain.

The roadshow will connect leading Israeli AI-driven drug discovery and biotechnology companies with U.S. investors, pharmaceutical companies, and potential strategic partners REHOVOT, Israel, Oct. 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for pharmaceutical and agricultural applications, today announced its participation in the AI Drug Discovery Roadshow, taking place November 2-5, 2026, across the U.S. East Coast.

REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a comprehensive cooperation agreement (the "Agreement") with L.I.A.

Evogene (NASDAQ: EVGN - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Institutional and Insider Ownership 10.4% of Evogene shares